Belgian Schizophrenia Outcome Survey - Results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol

European Psychiatry

Volumn 24, Issue 3, 2009, Pages 154-163

  Peuskens, J ^a   Gillain, B ^b   De Graeve, D ^c   Van Vleymen, B ^d   Albert, A ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d Eli Lilly Benelux   (Belgium)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Haloperidol; Maintenance treatment; Olanzapine; Risperidone; Schizophrenia; Treatment continuation

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; OLANZAPINE; PSYCHOTROPIC AGENT; RISPERIDONE;

ACUTE DISEASE; ADULT; AKATHISIA; AKINESIA; AMENORRHEA; ANORGASMIA; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DYSKINESIA; DYSTONIA; EDUCATIONAL STATUS; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; GALACTORRHEA; GYNECOMASTIA; HEALTH CARE COST; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPOKINESIA; INSTITUTIONALIZATION; LIBIDO; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; NATURALISTIC INQUIRY; OUTPATIENT CARE; PRIORITY JOURNAL; RIGIDITY; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SEXUAL DYSFUNCTION; SIDE EFFECT; TREMOR; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BELGIUM; BENZODIAZEPINES; BRIEF PSYCHIATRIC RATING SCALE; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 63449122123     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2008.11.002     Document Type: Article

References (23)

1. Bobes J., Garc A-Portilla M.P., Rejas J., Hern Ndez G., Garcia-Garcia M., Rico-Villademoros F., et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 29 (2003) 125-147
2. Csernansky J.G., Mahmoud R., and Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346 (2002) 16-22
3. Davis J.M., and Chen N. Old versus new: weighing the evidence between the first-and second generation antipsychotics. Eur Psychiatry 20 1 (2005) 7-14
4. Davis J.M., Chen N., and Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60 6 (2003) 553-564
5. De Graeve D., Peuskens J., Gillain B., Albert A., Debackere N., and Van Vleymen B. A description of direct medical costs in patients with schizophrenia and initiated on haloperidol, olanzapine or risperidone. Acta Psychiatrica Belgica 107/4 (2007) 31-39
6. De Hert M., Thys E., Boydens J., Gilis P., Kesteloot K., Verhaegen L., et al. Health care expenditure on schizophrenia patients in Belgium. Schizophr Bull 24 (1998) 519-527
7. Dossenbach M., Erol A., el Mahfoud Kessaci M., Shaheen M.O., Sunbol M.M., Boland J., et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 65 (2004) 312-321
8. Guy W. Clinical global impression. ECDEU Assessment Manual for Psychopharmacology (revised) (1976), National Institute of Mental Health, Rockville, MD 217-221
9. Haro J.M., Novick D., Suarez D., Alonso J., Lépine J.P., and Ratcliffe M. SOHO study group. Remission and relapse in the outpatient care of schizophrenia: 3-year result from SOHO study. J Clin Psychopharmacol 26 6 (2006) 571-578
10. Hennekens C.H., Hennekens A.R., Hollar D., and Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150 (2005) 1115-1121
11. http://statbel.fgov.be
12. Jones S.H., Thornicroft G., Coffey M., and Dunn G. A brief mental health outcome scale - reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 166 (1995) 654-659
13. Kay S., Ople L., and Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual (1986), Multi-Health Systems, North Tonawada, New York
14. Knegtering H., Boks M., Blijd C., and Castelein S. van den Bosch RJ, Wiersma D. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther 32 (2006) 315-326
15. Leucht S., Barnes T.R., Kissling W., Engel R.R., Correll C., and Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160 7 (2003) 1209-1222
16. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
17. Mazzaglia G., Mantovani L.G., Sturkenboom M.C., Filippi A., Trifiro G., Cricelli C., et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 23 (2005) 2093-2100
18. Peuskens J., Moore N., Azorin J.M., Toumi M., and Cochran J. The European Sertindole Safety and exposure survey: a follow-up of 8600 patients. Pharmacoepidemiol Drug Saf 16 (2007) 1-8
19. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29 (2003) 15-31
20. Tiihonen J., Wahlbeck K., Lönnqvist J., Klaukka T., Ioannidis J.P.A., Volavka J., et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333 (2006) 224-229
21. Tollefson G.D., Beasley Jr. C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154 (1997) 457-465
22. Tran P.V., Dellva M.A., Tollefson G., and Wentley A.L. Beasley CM Jr. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 172 (1998) 499-505
23. Williams R., Kopala L., Malla A., Smith G., Love L., and Balshaw R. Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia. Acta Psychiatr Scand 113 Suppl 430 (2006) 12-21